Carbapenem-resistant Infections After Liver Transplantation: Drug Resistance, Risk Factors and Impact on Prognosis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2025 Mar 10

PMID 40062326

Authors

Tao-Hua Liu

Li-Hua Chen

Qi-Quan Wan

Affiliations

Soon will be listed here.

Abstract

Background: Liver transplant (LT) recipients are susceptible to carbapenem-resistant (CRKP) infections. Comprehensive research addressing the incidence, timing, infection sites, resistance patterns, treatment options, and associated risk factors among LT recipients with CRKP is now lacking.

Aim: To assess the incidence, resistance, therapy, and risk factors of CRKP infections post-LT, and to evaluate the impact of them on prognosis.

Methods: A retrospective study was conducted, including 430 consecutive patients who underwent LT between January 2015 and June 2023. This study aimed to investigate the risk factors for CRKP infections and their influence on outcomes using logistic regression analysis.

Results: Among the 430 patients who underwent LT, 20 (4.7%) experienced at least one documented CRKP infection within 3 months post-transplantation. The median time from LT to the onset of CRKP infections was 6.5 days. The lungs and bloodstream were the most common sites of CRKP infections. CRKP isolates were relatively susceptible to ceftazidime/avibactam (93.7%), polymyxin B (90.6%), and tigecycline (75.0%) treatment. However, all isolates were resistant to piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, meropenem, and levofloxacin treatment. Recipients with CRKP infections had a mortality rate of 35%, the rate was 12.5% for those receiving ceftazidime/avibactam therapy. Multivariate analysis identified female sex [odds ratio (OR) = 3.306; 95% confidence interval (CI): 1.239-8.822; = 0.017], intraoperative bleeding ≥ 3000 mL (OR = 3.269; 95%CI: 1.018-10.490; = 0.047), alanine aminotransferase on day 1 post-LT ≥ 1500 U/L (OR = 4.370; 95%CI: 1.686-11.326; = 0.002), and post-LT mechanical ventilation (OR = 2.772; 95%CI: 1.077-7.135; = 0.035) as significant variables associated with CRKP. CRKP infections were related to an intensive care unit length (ICU) of stay ≥ 7 days and 6-month all-cause mortality post-LT.

Conclusion: CRKP infections were frequent complications following LT, with poor associated outcomes. Risk factors for post-LT CRKP infections included female sex, significant intraoperative bleeding, elevated alanine aminotransferase levels, and the need for mechanical ventilation. CRKP infections negatively impacted survival and led to prolonged ICU stays.

References

Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J . Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011; 55(7):3284-94. PMC: 3122440. DOI: 10.1128/AAC.01733-10. View

Mouloudi E, Massa E, Piperidou M, Papadopoulos S, Iosifidis E, Roilides I . Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant Proc. 2014; 46(9):3219-21. DOI: 10.1016/j.transproceed.2014.09.160. View

Varghese J, Gomathy N, Rajashekhar P, Venugopal K, Olithselvan A, Vivekanandan S . Perioperative bacterial infections in deceased donor and living donor liver transplant recipients. J Clin Exp Hepatol. 2015; 2(1):35-41. PMC: 3940144. DOI: 10.1016/S0973-6883(12)60081-4. View

Chen F, Zhong H, Yang T, Shen C, Deng Y, Han L . Ceftazidime-Avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant in Liver Transplantation Recipients. Infect Drug Resist. 2022; 14:5603-5612. PMC: 8710070. DOI: 10.2147/IDR.S342163. View

Shields R, Nguyen M, Chen L, Press E, Kreiswirth B, Clancy C . Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob Agents Chemother. 2018; 62(5). PMC: 5923134. DOI: 10.1128/AAC.02497-17. View

Spiliopoulou I, Kazmierczak K, Stone G . In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17). J Antimicrob Chemother. 2019; 75(2):384-391. PMC: 6966093. DOI: 10.1093/jac/dkz456. View

Liu N, Yang G, Dang Y, Liu X, Chen M, Dai F . Epidemic, risk factors of carbapenem-resistant infection and its effect on the early prognosis of liver transplantation. Front Cell Infect Microbiol. 2022; 12:976408. PMC: 9584088. DOI: 10.3389/fcimb.2022.976408. View

Horan T, Andrus M, Dudeck M . CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36(5):309-32. DOI: 10.1016/j.ajic.2008.03.002. View

Lubbert C, Becker-Rux D, Rodloff A, Laudi S, Busch T, Bartels M . Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. 2013; 42(2):309-16. DOI: 10.1007/s15010-013-0547-3. View

10.

Mouloudi E, Massa E, Papadopoulos S, Iosifidis E, Roilides I, Theodoridou T . Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae among intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact of resistance on outcomes. Transplant Proc. 2014; 46(9):3216-8. DOI: 10.1016/j.transproceed.2014.09.159. View

11.

Garzoni C, Ison M . Uniform definitions for donor-derived infectious disease transmissions in solid organ transplantation. Transplantation. 2011; 92(12):1297-300. DOI: 10.1097/TP.0b013e318236cd02. View

12.

Kaido T, Mori A, Ogura Y, Ogawa K, Hata K, Yoshizawa A . Pre- and perioperative factors affecting infection after living donor liver transplantation. Nutrition. 2012; 28(11-12):1104-8. DOI: 10.1016/j.nut.2012.02.007. View

13.

Liu P, Li X, Luo M, Xu X, Su K, Chen S . Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection: A Meta-Analysis. Microb Drug Resist. 2017; 24(2):190-198. PMC: 5873294. DOI: 10.1089/mdr.2017.0061. View

14.

Barchiesi F, Montalti R, Castelli P, Nicolini D, Staffolani S, Mocchegiani F . Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients. BMC Infect Dis. 2016; 16(1):538. PMC: 5050725. DOI: 10.1186/s12879-016-1876-5. View

15.

Abbott K, Oliver 3rd J, Hypolite I, Lepler L, Kirk A, Ko C . Hospitalizations for bacterial septicemia after renal transplantation in the united states. Am J Nephrol. 2001; 21(2):120-7. DOI: 10.1159/000046234. View

16.

Giannella M, Bartoletti M, Morelli M, Tedeschi S, Cristini F, Tumietto F . Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization. Am J Transplant. 2015; 15(6):1708-15. DOI: 10.1111/ajt.13136. View

17.

Lubbert C, Rodloff A, Laudi S, Simon P, Busch T, Mossner J . Lessons learned from excess mortality associated with Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in liver transplant recipients. Liver Transpl. 2014; 20(6):736-8. DOI: 10.1002/lt.23858. View

18.

Kalpoe J, Sonnenberg E, Factor S, Del Rio Martin J, Schiano T, Patel G . Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012; 18(4):468-74. DOI: 10.1002/lt.23374. View

19.

Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C . Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance.... Clin Infect Dis. 2022; 75(2):187-212. PMC: 9890506. DOI: 10.1093/cid/ciac268. View

20.

van Duin D, Kaye K, Neuner E, Bonomo R . Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013; 75(2):115-20. PMC: 3947910. DOI: 10.1016/j.diagmicrobio.2012.11.009. View